于忠英袁志△ 张伟李岩陈钊马志军喻元.重组合异种骨治疗股骨非感染性骨不连的长期疗效观察[J].,2012,12(7):1303-1305 |
重组合异种骨治疗股骨非感染性骨不连的长期疗效观察 |
Long-Term Efficacy Observation of Recombinant Bone Xenograft inTreatment of Femoral Non-Infected Nonunion |
|
DOI: |
中文关键词: 股骨 骨不连 骨移植 异种骨 |
英文关键词: Femur Nonunion Bone transplantation Xenogeneic bone |
基金项目: |
|
摘要点击次数: 1007 |
全文下载次数: 1148 |
中文摘要: |
目的:探讨重组合异种骨治疗股骨非感染性骨不连的长期临床疗效。方法:对2000 年1 月至2006 年9 月间我院应用重组
合异种骨(RBX)治疗的37 例股骨非感染性骨不连患者进行回顾性分析,其中男26 例,女11 例;年龄4~70 岁,平均31.6 岁。骨折
部位:股骨近端4 例,中段30 例,远端3 例。骨不连类型:肥大型9 例,营养不良型6 例,萎缩型22 例。固定方式:加压钢板24 例,
髓内钉11 例,外固定架2 例。结果:37 例患者获得51-131 个月的随访,平均90.2 个月,骨不连一次手术愈合率:94.6%,4 例股骨
近端骨不连患者采用Harris 评分系统评定疗效,优3 例,良1 例,差0 例,优良率100%。3 例股骨远端骨不连患者采用美国膝关节
协会评分系统(KSS)评定疗效,优1 例,例良1 例,差1 例,优良率66.7%。30 例股骨干骨不连患者采用Harris 评分系统和KSS 评
定疗效,优21 例,良8 例,差1 例,优良率96.7。总优良率94.6%。长期观察均无免疫排斥反应表现。结论:RBX 用于治疗股骨非
感染性骨不连具有材料充足、骨折愈合率高、组织兼容性好长期应用无免疫排斥反应等优点,是一种良好的自体骨替代材料。 |
英文摘要: |
Objective: To evaluate long-term efficacy of recombinant bone xenograft in treatment of femoral non-infected
nonunion. Methods: 37 patients suffered with femoral non-infected nonunion since 2000 was analyzed retrospectively,which included 26
males and 11 females,with the mean age of 31.6 years (ranged from 4 to 70 years). The nonunion site: the proximal femur in 4 cases, the
middle 30 cases, 3 cases of distal. There were 9 hypertrophic, 6 malnourished, 22 atrophic. 24 cases with plate,11 cases with
intramedullary nailing and 2 cases with external fixation. Results: The average follow-up time of these cases was 90.2 months,from 51
months to 131 months. 94.6% of these patients healed with only one operation. By the Harris scale ,of the 4case of proximal femoral
nonunion, the hip functions were rate as excellent in 3,good in 4 and no fair,with an excellent to good rate of 100%. By the American
Knee Society Score (KSS), of the 3cases of distal femoral nonunion,the knee function was rated as excellent in 1,good in 1 and fair in 1,
with an excellent to good rate of 66.7%. By the sanders Kss systems,of the 30 cases of femoral shaft nonunion,the hip and knee functions
were rated as excellent in 21,good in 8 and fair in 1,with an excellent to good rate of 96.7%.The total excellent to good rate was 94.6%.
No one has immune rejection in this long-term observation. Conclusion: RBX for the treatment of femoral non-infected nonunion has
many advantages,such as sufficient materia, high rate of fracture healing ,a nice biological compatibility,it can be used in the clinic
instead of autologous bone. |
查看全文
查看/发表评论 下载PDF阅读器 |
关闭 |
|
|
|